{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T03:39:06Z","timestamp":1791085146746,"version":"4.1.0"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Immunology"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.clim.2024.110239","type":"journal-article","created":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T15:35:24Z","timestamp":1715268924000},"page":"110239","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["The safety and efficacy of TNF inhibitors in patients with Beh\u00e7et's disease: Retrospective study from eastern Turkey"],"prefix":"10.1016","volume":"264","author":[{"given":"Murat","family":"Bekta\u015f","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammet Derda","family":"\u00d6zer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emin","family":"O\u011fuz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.clim.2024.110239_bb0005","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1136\/bjo.2007.124875","article-title":"Beh\u00e7et\u2019s disease: global epidemiology of an old silk road disease","volume":"91","author":"Keino","year":"2007","journal-title":"Br. J. Ophthalmol."},{"issue":"6 Suppl 94","key":"10.1016\/j.clim.2024.110239_bb0010","first-page":"S60","article-title":"Tracing Beh\u00e7et\u2019s disease origins along the silk road: an anthropological evolutionary genetics perspective","volume":"33","author":"Sazzini","year":"2015","journal-title":"Clin. Exp. Rheumatol."},{"issue":"1","key":"10.1016\/j.clim.2024.110239_bb0015","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1097\/BOR.0000000000000846","article-title":"The association of Beh\u00e7et\u2019s syndrome with HLA-B51 as understood in 2021","volume":"34","author":"Takeno","year":"2022","journal-title":"Curr. Opin. Rheumatol."},{"issue":"1","key":"10.1016\/j.clim.2024.110239_bb0020","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/s41572-021-00301-1","article-title":"Beh\u00e7et syndrome","volume":"7","author":"Yazici","year":"2021","journal-title":"Nat. Rev. Dis. Primers"},{"issue":"4","key":"10.1016\/j.clim.2024.110239_bb0025","doi-asserted-by":"crossref","first-page":"735","DOI":"10.3899\/jrheum.130847","article-title":"Colchicine in Beh\u00e7et syndrome: a longterm survey of patients in a controlled trial","volume":"41","author":"Hamuryudan","year":"2014","journal-title":"J. Rheumatol."},{"issue":"9","key":"10.1016\/j.clim.2024.110239_bb0030","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1093\/rheumatology\/kez598","article-title":"Long term follow-up of Beh\u00e7et\u2019s syndrome patients treated with cyclophosphamide","volume":"59","author":"Gurcan","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.clim.2024.110239_bb0035","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.3389\/fimmu.2019.02830","article-title":"Treating the different phenotypes of Beh\u00e7et\u2019s syndrome","volume":"10","author":"Bettiol","year":"2019","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.clim.2024.110239_bb0040","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.berh.2016.08.002","article-title":"Beh\u00e7et\u2019s disease: how to diagnose and treat vascular involvement","volume":"30","author":"Seyahi","year":"2016","journal-title":"Best Pract. Res. Clin. Rheumatol."},{"issue":"9","key":"10.1016\/j.clim.2024.110239_bb0045","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21093072","article-title":"Beh\u04abet\u2019s disease, and the role of TNF-\u03b1 and TNF-\u03b1 blockers","volume":"21","author":"van der Houwen","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.clim.2024.110239_bb0050","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jaut.2015.06.005","article-title":"Efficacy of anti-TNF alpha in severe and\/or refractory Beh\u00e7et\u2019s disease: multicenter study of 124 patients","volume":"62","author":"Vallet","year":"2015","journal-title":"J. Autoimmun."},{"issue":"6","key":"10.1016\/j.clim.2024.110239_bb0055","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1136\/annrheumdis-2018-213225","article-title":"2018 update of the EULAR recommendations for the management of Beh\u00e7et\u2019s syndrome","volume":"77","author":"Hatemi","year":"2018","journal-title":"Ann. Rheum. Dis."},{"issue":"8697","key":"10.1016\/j.clim.2024.110239_bb0060","first-page":"1078","article-title":"International study Group for Beh\u00e7et\u2019s disease","volume":"335","author":"Criteria for diagnosis of Beh\u00e7et\u2019s disease","year":"1990","journal-title":"Lancet (Lond., Engl.)."},{"issue":"3","key":"10.1016\/j.clim.2024.110239_bb0065","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1111\/jdv.12107","article-title":"The international criteria for Beh\u00e7et's disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria","volume":"28","year":"2014","journal-title":"J. Eur. Acad. Dermatol. Venereol.: JEADV."},{"issue":"11","key":"10.1016\/j.clim.2024.110239_bb0070","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1093\/rheumatology\/keu233","article-title":"Vascular involvement in Beh\u00e7et\u2019s syndrome: a retrospective analysis of associations and the time course","volume":"53","author":"Tascilar","year":"2014","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"10.1016\/j.clim.2024.110239_bb0075","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1136\/annrheumdis-2016-210770","article-title":"2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis","volume":"76","author":"van der Heijde","year":"2017","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"10.1016\/j.clim.2024.110239_bb0080","doi-asserted-by":"crossref","first-page":"81","DOI":"10.2174\/1568010053622894","article-title":"Beh\u00e7et\u2019s disease as an autoinflammatory disorder","volume":"4","author":"G\u00fcl","year":"2005","journal-title":"Curr. Drug Targets Inflamm. Allergy"},{"issue":"12","key":"10.1016\/j.clim.2024.110239_bb0085","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/nrrheum.2015.147","article-title":"\u2018MHC-I-opathy\u2019-unified concept for spondyloarthritis and Beh\u00e7et disease","volume":"11","author":"McGonagle","year":"2015","journal-title":"Nat. Rev. Rheumatol."},{"issue":"3","key":"10.1016\/j.clim.2024.110239_bb0095","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1182\/blood-2011-04-325225","article-title":"Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey","volume":"119","author":"Aggarwal","year":"2012","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.clim.2024.110239_bb0100","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1007\/s10067-015-2966-2","article-title":"Possible association of proinflammatory cytokines including IL1\u03b2 and TNF\u03b1 with enhanced Th17 cell differentiation in patients with Behcet\u2019s disease","volume":"35","author":"Shimizu","year":"2016","journal-title":"Clin. Rheumatol."},{"issue":"11","key":"10.1016\/j.clim.2024.110239_bb0105","doi-asserted-by":"crossref","first-page":"5799","DOI":"10.4049\/jimmunol.1202677","article-title":"Role of IL-22- and TNF-\u03b1-producing Th22 cells in uveitis patients with Behcet\u2019s disease","volume":"190","author":"Sugita","year":"2013","journal-title":"J. Immunol."},{"key":"10.1016\/j.clim.2024.110239_bb0110","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.imlet.2016.12.001","article-title":"An elevated pro-inflammatory cytokines profile in Behcet\u2019s disease: a multiplex analysis","volume":"186","author":"Gholijani","year":"2017","journal-title":"Immunol. Lett."},{"issue":"1","key":"10.1016\/j.clim.2024.110239_bb0115","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/j.1365-2230.2004.01684.x","article-title":"Serum interleukin 18 and tumour necrosis factor-alpha levels are increased in Behcet\u2019s disease","volume":"30","author":"Oztas","year":"2005","journal-title":"Clin. Exp. Dermatol."},{"issue":"2","key":"10.1016\/j.clim.2024.110239_bb0120","first-page":"321","article-title":"Cytokines in Beh\u00e7et\u2019s disease","volume":"23","author":"Sayinalp","year":"1996","journal-title":"J. Rheumatol."},{"issue":"6","key":"10.1016\/j.clim.2024.110239_bb0125","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1089\/jir.2018.0116","article-title":"Role of serum miR-181b, Proinflammatory cytokine, and adhesion molecules in Beh\u00e7et\u2019s disease","volume":"39","author":"El Boghdady","year":"2019","journal-title":"J. Interf. Cytokine Res.: Off. J. Intern. Soc. Interf. Cytok. Res."},{"issue":"10","key":"10.1016\/j.clim.2024.110239_bb0130","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1002\/art.41042","article-title":"2019 update of the American College of Rheumatology\/spondylitis Association of America\/Spondyloarthritis research and treatment network recommendations for the treatment of ankylosing spondylitis and nonradiographic axial Spondyloarthritis","volume":"71","author":"Ward","year":"2019","journal-title":"Arthritis Rheumatol. (Hoboken, NJ)."},{"issue":"12","key":"10.1016\/j.clim.2024.110239_bb0135","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/S2468-1253(21)00312-5","article-title":"Comparative efficacy and safety of biologic therapies for moderate-to-severe Crohn\u2019s disease: a systematic review and network meta-analysis","volume":"6","author":"Singh","year":"2021","journal-title":"Lancet Gastroenterol. Hepatol."},{"issue":"11","key":"10.1016\/j.clim.2024.110239_bb0140","doi-asserted-by":"crossref","first-page":"2967","DOI":"10.1007\/s10067-019-04684-1","article-title":"Defining response to TNF-inhibitors in rheumatoid arthritis: the negative impact of anti-TNF cycling and the need for a personalized medicine approach to identify primary non-responders","volume":"38","author":"Johnson","year":"2019","journal-title":"Clin. Rheumatol."},{"issue":"1","key":"10.1016\/j.clim.2024.110239_bb0145","first-page":"98","article-title":"Short-term trial of etanercept in Beh\u00e7et\u2019s disease: a double blind, placebo controlled study","volume":"32","author":"Melikoglu","year":"2005","journal-title":"J. Rheumatol."},{"issue":"2","key":"10.1016\/j.clim.2024.110239_bb0150","first-page":"171","article-title":"Mucosal healing at 14 weeks predicts better outcome in low-dose infliximab treatment for Chinese patients with active intestinal Behcet\u2019s disease","volume":"47","author":"Zou","year":"2017","journal-title":"Ann. Clin. Lab. Sci."},{"issue":"9","key":"10.1016\/j.clim.2024.110239_bb0155","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1016\/j.ophtha.2018.02.020","article-title":"Successful optimization of adalimumab therapy in refractory uveitis due to Beh\u00e7et\u2019s disease","volume":"125","author":"Mart\u00edn-Varillas","year":"2018","journal-title":"Ophthalmology"},{"issue":"6","key":"10.1016\/j.clim.2024.110239_bb0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajo.2008.09.010","article-title":"Infliximab effects compared to conventional therapy in the management of retinal vasculitis in Beh\u00e7et disease","volume":"146","author":"Tabbara","year":"2008","journal-title":"Am. J. Ophthalmol."},{"issue":"3","key":"10.1016\/j.clim.2024.110239_bb0165","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1136\/bjo.2009.158840","article-title":"Comparison of infliximab versus ciclosporin during the initial 6-month treatment period in Beh\u00e7et disease","volume":"94","author":"Yamada","year":"2010","journal-title":"Br. J. Ophthalmol."},{"issue":"6","key":"10.1016\/j.clim.2024.110239_bb0170","first-page":"86","article-title":"Infliximab for uveitis of Beh\u00e7et\u2019s syndrome: a trend for earlier initiation","volume":"35 Suppl 108","author":"Guzelant","year":"2017","journal-title":"Clin. Exp. Rheumatol."},{"issue":"9","key":"10.1016\/j.clim.2024.110239_bb0175","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1002\/art.40531","article-title":"Adalimumab-based treatment versus disease-modifying Antirheumatic drugs for venous thrombosis in Beh\u00e7et\u2019s syndrome: a retrospective study of seventy patients with vascular involvement","volume":"70","author":"Emmi","year":"2018","journal-title":"Arthritis Rheumatol. (Hoboken, NJ)."},{"key":"10.1016\/j.clim.2024.110239_bb0180","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jaut.2015.06.005","article-title":"Efficacy of anti-TNF alpha in severe and\/or refractory Beh\u00e7et\u2019s disease: multicenter study of 124 patients","volume":"62","author":"Vallet","year":"2015","journal-title":"J. Autoimmun."},{"issue":"1","key":"10.1016\/j.clim.2024.110239_bb0185","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1093\/rheumatology\/keu247","article-title":"Gender-specific differences in Adamantiades-Beh\u00e7et\u2019s disease manifestations: an analysis of the German registry and meta-analysis of data from the literature","volume":"54","author":"Bonitsis","year":"2015","journal-title":"Rheumatology (Oxford)"}],"container-title":["Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661624003486?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661624003486?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,2]],"date-time":"2025-02-02T01:21:08Z","timestamp":1738459268000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521661624003486"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":36,"alternative-id":["S1521661624003486"],"URL":"https:\/\/doi.org\/10.1016\/j.clim.2024.110239","relation":{},"ISSN":["1521-6616"],"issn-type":[{"value":"1521-6616","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The safety and efficacy of TNF inhibitors in patients with Beh\u00e7et's disease: Retrospective study from eastern Turkey","name":"articletitle","label":"Article Title"},{"value":"Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clim.2024.110239","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"110239"}}